Groundbreaking Olive Oil-Derived Drug Shows Promise in Treating Brain Cancer

Groundbreaking Olive Oil-Derived Drug Shows Promise in Treating Brain Cancer

'Olive oil' drug offers hope for patients with incurable brain tumours

A recent NHS trial has indicated that a drug derived from oleic acid, naturally found in olive oil, could be a potential treatment for patients with glioblastomas, the most common form of cancerous brain tumours. This groundbreaking medication, known as idroxioleic acid or 2-OHOA, has shown promising results in treating this aggressive and often fatal disease.

Positive Response in Patients with Glioblastoma

Researchers observed that approximately a quarter of patients with glioblastomas responded well to the treatment with 2-OHOA. One patient even had an "exceptional response" that lasted for over three years. These encouraging results have led to further global trials focusing on newly diagnosed patients with brain tumours.

New Approach to Treatment

2-OHOA is considered a first-in-class treatment as it offers a unique way of combating the disease by restructuring the abnormal cell membranes of cancer cells. By blocking crucial growth signals, the drug aims to inhibit the growth of cancer cells effectively. Administered in a sachet form, similar to Lemsip, 2-OHOA is taken three times a day with water.

Patients Share Their Stories

Michele Treen, a patient diagnosed with glioblastoma, shared her experience with the trial. After quickly reorganizing her wedding and undergoing brain surgery, Michele joined the 2-OHOA trial at The Royal Marsden. Despite experiencing some side effects, she remains hopeful and grateful for the opportunity to participate in the study, which has given her newfound hope and allowed her to continue doing things she loves with her family.

Groundbreaking Olive Oil-Derived Drug Shows Promise in Treating Brain Cancer

Expert Insights and Hope for the Future

Healthcare professionals and experts in the field of cancer research have emphasized the importance of accelerating drug development for patients with brain tumours. Phase three clinical trials are underway to further assess the effectiveness of 2-OHOA and its potential to extend the life expectancy of patients with glioblastoma. The progress of this innovative treatment is a significant step forward in providing better options for individuals facing this devastating diagnosis.

Did you miss our previous article...